| Phase 12 trials |
|
Phase 1
|
NCT07414953 |
Mar 2026 → Apr 2027 expected |
lung cancer |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06094556 |
Dec 2023 → Jun 2027 expected |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06754930 |
Feb 2025 → Dec 2027 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06703177 |
Feb 2025 → Jan 2026 overdue |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07704645 |
Aug 2026 → Jun 2028 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07489716 |
Apr 2026 → Aug 2028 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06935175 |
May 2025 → May 2027 expected |
hepatocellular carcinoma |
Shanghai Zhongshan Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06915142 |
Apr 2025 → Dec 2026 expected |
cancer |
Shandong Suncadia Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06844474 |
Mar 2025 → Dec 2026 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|